**Acknowledgement**

The authors would like to thank the following cooperating companies for the financial and organizational support of the entire project: N-ERGIE AG (Germany), N-ERGIE Netz GmbH (Germany), N-ERGIE Service GmbH (Germany), Bayerische Kabelwerke AG (Germany).

#### **10. References**

1407, I. S. (1998). IEEE Trial-Use Guide for Accelerated Aging Tests for Medium-Voltage Extruded Electric Power Cables Using Water-Filled Tanks.

Empiric Approach for Criteria Determination of Remaining Lifetime Estimation of MV PILC Cables 279

Freitag, C. (2008). *Entwicklung und Implementierung eines Steuerungs-, Regelungs- und Messsystems zur Realisierung einer automatisierten Versuchsanlage für die beschleunigte Alterung von Mittelspannungskabeln.* Diploma Thesis, University of Erlangen-Nürnberg,

Freitag, C., Mladenovic, I., & Weindl, C. (2010). Fully Automated MV Cable Monitoring and Measurement System for Multi-Sample Acquisition of Artificial Aging Parameters.

Freitag, C., Weindl, C., & Mladenovic, I. (2011). On-Line Cable Diagnostic Possibilities in an

Glaubitz, W., Postler, H., Rittinghaus, D., Seel, G., Sengewald, F., & Winkler, F. (1989). *Kabel und Leitungen für Starkstrom - Teil 2* (4. ed.). (L. H. Stubbe, Ed.) Germany: Siemens

Kock, J. d., & Strauss, C. (2004). *Practical Power Distribution for Industry* (1 ed.). (Newnes, Ed.)

Kuhnert, Wieznerowicz, & Wanser. (1997). *Eigenschaften von Energiekabeln und deren Messung*

Lemke, E. (2008). *Guide for partial discharge measurements in compliance to IEC 60270.* Germany. Mladenovic I., W. C. (2009). New System for MV-Cable ageing under controlled conditions. *Congrès international des Réseaux électriques de Distribution 2009, CIRED.* Tschech Republic. Mladenovic, I. (2012, to be published). *Determination of the Remaining Lifetime of PILC cables based on PD and tan(δ) diagnostics.* Doctoral Thesis, University of Erlangen-Nuremberg, Erlangen. Mladenovic, I., & Weindl, C. (2012, January/February). Artificial Aging and Diagnostic Measurements on Medium-Voltage, Paper-Insulated, Lead-Covered Cables. *IEEE*

Mladenovic, I., & Weindl, C. (2012). Comparison of the parametric Partial Discharges and Dissipation factor Characteristics of MV PILC Cables. *IEEE International Symposium on*

Mladenovic, I., & Weindl, C. (2011). Dependencies of the PD- and tan(δ)-Characteristics on the Temperature and Ageing Status of MV PILC Cables. *Electrical Insulation Conference -*

Mladenovic, I., & Weindl, C. (2011). Dependency of the Dissipation Factor on the Test-Voltage and the Ageing Status of MV PILC Cables. *Jicable11.* Versailles, France. Mladenovic, I., & Weindl, C. (2008). Determination of the Characteristic Life Time of Paperinsulated MV-Cables based on a Partial Discharge and tan(δ) Diagnosis. *14th*

*International Power Electronics and Motion Control Conference EPE-PEMC.* Poland. Mladenovic, I., & Weindl, C. (2009). Determination of the Environmental Conditions for the Accelerated Ageing of MV-PILC Cables. *9th International Conference on Properties and*

Mladenovic, I., & Weindl, C. (2010). Development of the Partial Discharges Inception Voltage for Different Sets of Pre-Aged PILC Cable Samples. *International Symposium on*

Artificial Aging Environment. *ICREPQ 2011.* Spain.

Küchler, A. (2009). *Hochspannungstechnik.* Berlin: Springer.

*Electrical insulation Magazine*, *28* (1), pp. 20-26.

*Electrical Insulation - ISEI 2012.* Puerto Rico.

*Applications of Dielectric Materials, ICPADM.* China.

*Electrical Insulation, ISEI.* San Diego, USA.

(2. Edition ed.). Frankfurt am Main, Germany: VWEW.

High Voltage - VLF Hipot Instruments. (n.d.). Tan δ (Delta) Cable Testing.

Erlangen, Germany.

*ICREPQ.* Spain.

Aktiengesellschaft.

Oxford, UK: Elsevier.

*EIC.* Annapolis, USA.

278 Dielectric Material

**10. References**

Power Cable Systems.

Low Frequency (VLF).

(p. ID 289). Cairo University, Egypt.

Colebrook, M. (n.d.). Retrieved from Green spirit: www.greenspirit.org.uk/resources/cellulose.gif

degradation of cellulose. *Cellulose* (1), 26-56.

Thesis, University of Erlangen-Nuremberg, Erlangen.

300, Mannheim.

*und praktische Grundlagen für die Anwendung.* Soringer.

*AIEE Summer General Meeting*, (pp. 687-696). Montreal, Canada.

1407, I. S. (1998). IEEE Trial-Use Guide for Accelerated Aging Tests for Medium-Voltage

(2010). Retrieved from www.wikieduc.ch: www.wikieduc.ch/images/7/71/Isolierstoffe.doc 400, I. S. (2001). "IEEE Guide for Field Testing and Evaluation of the Insulation of Shielded

400.2, I. S. (2004). IEEE Guide for Field Testing of Shielded Power Cable Systems Using Very

62478, I. (2011). High voltage test techniques - Measurement of partial discharges by

Ambikairajah, R., Phung, B. T., Ravishankar, J., Blackburn, T. R., & Liu, Z. (2010). Smart Sensors and Online Condition Monitoring of High Voltage Cables for the Smart Grid. *roceedings of the 14 th International Middle East Power Systems Conference (MEPCON'10)*,

Bartnikas, R. (2002, October). Partial Discharges - Their Mechanism, Detection and Measurement. *IEEE Transactions on Dielectrics and Electrical Insulation*, *9* (5), pp. 763-808. Bayer, M., Boeck, W., Möller, K., & Zaengl, W. (1986). *Hochspannungstechnik - Theoretische*

Bennett, G. E. (October 1957). Paper Cable Saturants: European Preferences and Selection.

Boltze, M., Markalous, S., Bolliger, A., Ciprietti, O., & Chiu, J. (2009). On-line partial discharge monitoring and diagnosis at power cables. *76th Annual International Doble Client Conference.*

Cuppen, A. N., Steennis, E. F., & van der Wielen, P. C. (2010). Partial Discharge Trends in Medium Voltage Cables measured while in-service with PDOL. *Transmission and*

Dr.-Ing. Weindl, C., & Dipl.-Ing. Mladenovic, I. (2009). Bestimmung von Restlebensdauer von Massekabeln anhand einer Teilentladungs- und tan(δ)-Diagnose. *Diagnostik*

Emsley, A. M., & Stevens, G. C. (1994). Kinetics and mechanisms of the low-temperature

FGH - Forschungsgemeinschaft für Elektrische Anlagen und Stromwirtschaft e. V.. (2006). *Zustandsdiagnose von Papiermasse-Kabelanlagen in Verteilungsnetzen.* Technischer Bericht

Freitag, C. (to be published). *Entwicklung und Anwendung optimierter Verfahren der Verlustfaktorbestimmung zur Diagnose von Mittelspannungskabeln (working title).* Doktoral

*Distribution Conference and Exposition, 2010 IEEE PES.* New Orleans, LA, USA. Densley, J. (2001, January/February). Ageing mechanisms and Diagnostics for Power Cables

*elektrischer Betriebsmittel - ETG Kongress.* Dusseldorf, Germany.

60270, I. (2000). High-voltage test techniques – Partial discharge measurements.

electromagnetic and acoustic methods "Proposed Horizontal Standard".

Extruded Electric Power Cables Using Water-Filled Tanks.

Mladenovic, I., & Weindl, C. (2009). ICAAS – Integrated System for lasting Accelerated Aging of MV Cables, Data Monitoring and Acquisition. *IEEE Conference on Electrical Insulation and Dielectric Phenomena 2009, CEIDP.* Virginia Beach, USA.

**Chapter 12**

© 2012 Prokopenko et al., licensee InTech. This is an open access chapter distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2012 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,

**Electromechanical Control over Effective**

**Permittivity Used for Microwave Devices**

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/50584

to fundamental physical reason.

millimetre wave range.

used to describe other devices as well.

**1. Introduction**

Yuriy Prokopenko, Yuriy Poplavko, Victor Kazmirenko and Irina Golubeva

Ferroelectrics are well known tunable dielectric materials. Permittivity of these materials can be controlled by an applied electrical bias field. Controllable permittivity leads to alteration of characteristics of tunable microwave components such as propagation constants, resonant frequency etc. However, dielectric losses in the ferroelectric-type tunable components are comparatively high and show substantial increase approaching to the millimetre waves due

Alternative way to achieve controllability of characteristics in tunable microwave devices is mechanical reconfiguration. In this case the alteration of microwave characteristics can be attained by displacement of dielectric or metallic parts of devices. Mechanical tuning is very promising to produce low insertion loss combined with good tunability in microwave subsystems. In the case of ferroelectric technique of tuning, microwaves interact with the ferroelectric material which is a part of microwave line. That is why transmitted energy is partially absorbed by this material. On the contrary, mechanical system of control is located out of microwave propagation route so it does not contribute to the microwave loss. Moreover, it will be shown that dielectric losses have a trend to reduce in such devices. Mechanical control is valid at any frequency range, including

Transformation of microwave characteristics could be described in terms of medium's effective dielectric permittivity (*eff*). Effective dielectric permittivity of inhomogeneous medium can be defined as dielectric permittivity of homogeneous medium, which brings numerically the same macro parameters to the system of the same geometrical configuration. Effective permittivity is convenient parameter to describe devices with TEM wave propagating, where propagation constant is proportional to *eff* , however it can be

and reproduction in any medium, provided the original work is properly cited.


**Author details**

Özgür Karcıoğlu

Department of Emergency Medicine, University of Health Sciences, Taksim Training and Research Hospital, Istanbul, Turkey

\*Address all correspondence to<EMAIL_ADDRESS>
© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Modern Medical Genetics and Genomics in the Era of Personalized/Precision Medicine

*Israel Gomy*

## **1. Introduction**

Modern medical genetics as a well-defined field of medicine has developed so fast since its origins half a century ago that we cannot bear in mind how long time ago its roots and beginnings came from.

It can be argued that genetics overall was based on measuring the problems of human hereditary features and inherited diseases, since before the twentiethcentury acceptance of Mendelian laws of heredity. Thus, medical genetics, viewed from its broadest perspective, is perhaps the oldest area of genetics and not a recent area that it is sometimes believed.

## **2. Modern genomics in medicine**

During the years, with developments in cellular and molecular biology, the field of medical genetics expanded from a small clinical subspecialty focused at describing a few rare hereditary disorders to a recognized medical specialty whose principles and approaches are essential parts of the diagnosis and management of many disorders, both common and rare. These genetic concepts and approaches are not restricted to any one medical specialty or subspecialty, as they permeate many, and perhaps all areas of medicine.

The medical geneticist is usually a physician who works as part of a team of clinical providers, including many other physicians, nurses, and genetic counselors, to evaluate patients and their relatives for possible hereditary diseases. They characterize the patient (or proband) through analyses of personal and family history and physical examination; assess risk and possible modes of inheritance; indicate diagnostic testing; manage prevention, treatment, and surveillance; and participate in communicating to other family members at risk for the disorder.

During the twentieth century, it gradually became clear that hereditary factors were implicated in many conditions and that different genetic mechanisms were involved. Virtually, any disease is the result of the interaction of genes and environment, but the relative influence of the genetic component may be large or small. Traditionally, genetic conditions have been classified into three categories: monogenic, chromosomal, and multifactorial disorders. However, it is becoming increasingly evident that the interplay of different genes (polygenic inheritance) is essential in disease and that an additional category—acquired somatic genetic disease—should also be included.

Improvements in all areas of medicine, mainly public health and therapeutics, resulted in modifying patterns of diseases, with improving recognition of the role of genetic factors for most of common disorders or even for the susceptibility to infectious diseases. For complex chronic degenerative diseases of adult onset, their overall contribution of heritability has been identified, as life expectancy increases and high-throughput technologies improve. These provide the opportunity for understanding the interactions between the genetic and environmental factors of diseases such as cancer, Alzheimer's disease, diabetes mellitus, macular degeneration, and cardiomyopathy.

In recent years, we have been facing the applications of modern genomics to the practice of medicine. With robust molecular biology technologies, one can identify the actionable mutations present in a tumor and establish the profile of its pattern of RNA expression, which are currently being used for determining prognosis and choosing appropriate targeted therapies for individual cancer patients. Another application is how modern genomic approaches are increasing our abilities in risk assessment and helping provide more accurate genetic counseling to patients and families affected with hereditary diseases as well as advances in prenatal diagnosis.

There are further examples of applications of genomics to individualized health care: screening asymptomatic individuals for genetic predisposition to various diseases in order to improve health care, population-based newborn screening for preventable and treatable genetic diseases, identifying couples that are carriers for autosomal recessive or X-linked diseases that could affect their children before conception, prenatal screening of the fetus for aneuploidy by maternal cell-free DNA, and applications of pharmacogenomics on the detection of individual variation affecting drug therapy, which can be used to improve therapeutic efficacy and reduce adverse events.

At the beginning of the twenty-first century, the Human Genome Project (HGP) provided a virtually complete sequence of human genome from which now derives the efforts to catalog all human genes, understand their structure and regulation, determine the extent of their variation in different populations, and uncover how genetic variation contributes to susceptibility. The whole genome of any individual can now be sequenced rather than sequencing one gene at a time. These achievements are making possible the practice of genomic medicine, which aims at applying a wide analysis of the human genome and its products, including the epigenetic regulation of gene expression, gene variation, and their interactions with the environment, to medical care.

The HGP has now been succeeded by the Human Variome Project, which seeks to compile and share the huge variation in human DNA sequence worldwide. This is potentially possible since whole exome sequencing (WES) and whole genome sequencing (WGS) have been increasingly performed in several population studies. For example, the 100,000 Genomes Project in the United Kingdom have recently achieved its goal of 100,000 genomes sequenced [1].

The study of genetics and its role in causing human disease is now widely acknowledged as being among the most exciting and influential areas of medical research. Certainly, their valuable discoveries have benefited patients and families dramatically, but this achievement will be measured by translating them into both treatment and prevention of disease.

#### **3. Diagnostic advances**

Advances over the past few years in mutation identification have provided many improvements in risk assessment, carrier detection, and prenatal diagnosis, allowing the detection of particular mutations with almost 100% accuracy. Laboratory testing for pathogenic (disease-causing) mutations is available for more than 4,500 genes associated to over 11,000 genetic conditions [2]. The better knowledge of the genes involved in hereditary disease and the rapidly

**5**

*Modern Medical Genetics and Genomics in the Era of Personalized/Precision Medicine*

cheaper cost of DNA sequencing have permitted the identification of mutations in a patient or family member, and, therefore, the molecular diagnosis has become the standard of care for many conditions. DNA samples for testing are available not only from readily accessible tissues, such as a buccal scraping or blood sample, but also from tissues obtained by more invasive testing, such as chorionic villus

For many hereditary disorders (including retinal degeneration, deafness, hereditary breast and ovarian cancer, Lynch syndrome, congenital myopathy, mitochondrial disorders, and hypertrophic or dilated cardiomyopathies), there is a substantial locus heterogeneity, that is, numerous genes are known to be mutated in different families with these disorders. When a patient with one of these highly heterogeneous disorders seeks for testing, recent advances in DNA sequencing make it possible to analyze large panels of dozens to more than 100 genes simultaneously and cost-effectively for mutations in every gene in which mutations have been seen

In those conditions for which even a large panel of relevant genes cannot be formulated for a particular phenotypically defined disorder, or for those genetically heterogeneous entities (e.g. intellectual disability, autism spectrum disorder) genetic diagnosis still can be achieved by analyzing all the coding exons of every gene (by WES) or by sequencing the entire genome (by WGS) to identify patho-

The use of large gene panels and, even more so, WGS or WES raises special issues for sequence interpretation and risk assessment. As there are more genes being tested, the number of sequence differences between a patient's DNA and that of an arbitrary reference sequence also increases; consequently, many previously undescribed variants will be found whose pathogenicity is unknown. These are so-called variants of uncertain significance (VUSs). This is the case, for example, of a missense mutation that results in the substitution of one amino acid for another in

Thus, the interpretation of variants is a challenging and demanding area for all professional geneticists who provide molecular diagnosis. The American College of Medical Genetics and Genomics has recommended that variants be categorized into one of five classes: pathogenic, likely pathogenic, of uncertain significance, likely benign, and benign variants [3] Specialists in molecular diagnostics, human genomics, and bioinformatics have developed a series of criteria for addressing the mutation status. In most cases, none of these criteria is absolutely definitive but must be considered together to provide an overall assessment of the pathogenicity of a variant. Only those variants with a high probability of being pathogenic are communicated to the health professional and patient. It is arguable whether the testing laboratory should disclosure all VUSs, at the same time remaining available for updating as new information allow reclassification as either benign or pathogenic. Despite all the time and effort put into interpretation, it is still impossible to ensure any clinical significance to the vast majority of all variants found through next-generation sequencing (NGS). There is a general concern that individuals and their clinical providers, when confronted with VUSs, will require additional unnecessary testing, with the potential for finding results with even more VUSs, thereby increasing patient's uncertainty and anxiety. Moreover, there is the additional concern that even when a variant is known to be pathogenic and highly penetrant in families with multiple affected individuals, the true penetrance of a variant when it

is found in individuals with a negative family history may be much lower.

communicating it properly to healthcare providers and patients.

Therefore, risk assessment and genetic counseling in this context are challenging processes and depend on continually addressing recently available information and

*DOI: http://dx.doi.org/10.5772/intechopen.84578*

sampling or amniocentesis.

previously to cause the disorder.

genic mutations.

the encoded protein.

#### *Modern Medical Genetics and Genomics in the Era of Personalized/Precision Medicine DOI: http://dx.doi.org/10.5772/intechopen.84578*

cheaper cost of DNA sequencing have permitted the identification of mutations in a patient or family member, and, therefore, the molecular diagnosis has become the standard of care for many conditions. DNA samples for testing are available not only from readily accessible tissues, such as a buccal scraping or blood sample, but also from tissues obtained by more invasive testing, such as chorionic villus sampling or amniocentesis.

For many hereditary disorders (including retinal degeneration, deafness, hereditary breast and ovarian cancer, Lynch syndrome, congenital myopathy, mitochondrial disorders, and hypertrophic or dilated cardiomyopathies), there is a substantial locus heterogeneity, that is, numerous genes are known to be mutated in different families with these disorders. When a patient with one of these highly heterogeneous disorders seeks for testing, recent advances in DNA sequencing make it possible to analyze large panels of dozens to more than 100 genes simultaneously and cost-effectively for mutations in every gene in which mutations have been seen previously to cause the disorder.

In those conditions for which even a large panel of relevant genes cannot be formulated for a particular phenotypically defined disorder, or for those genetically heterogeneous entities (e.g. intellectual disability, autism spectrum disorder) genetic diagnosis still can be achieved by analyzing all the coding exons of every gene (by WES) or by sequencing the entire genome (by WGS) to identify pathogenic mutations.

The use of large gene panels and, even more so, WGS or WES raises special issues for sequence interpretation and risk assessment. As there are more genes being tested, the number of sequence differences between a patient's DNA and that of an arbitrary reference sequence also increases; consequently, many previously undescribed variants will be found whose pathogenicity is unknown. These are so-called variants of uncertain significance (VUSs). This is the case, for example, of a missense mutation that results in the substitution of one amino acid for another in the encoded protein.

Thus, the interpretation of variants is a challenging and demanding area for all professional geneticists who provide molecular diagnosis. The American College of Medical Genetics and Genomics has recommended that variants be categorized into one of five classes: pathogenic, likely pathogenic, of uncertain significance, likely benign, and benign variants [3] Specialists in molecular diagnostics, human genomics, and bioinformatics have developed a series of criteria for addressing the mutation status. In most cases, none of these criteria is absolutely definitive but must be considered together to provide an overall assessment of the pathogenicity of a variant. Only those variants with a high probability of being pathogenic are communicated to the health professional and patient. It is arguable whether the testing laboratory should disclosure all VUSs, at the same time remaining available for updating as new information allow reclassification as either benign or pathogenic.

Despite all the time and effort put into interpretation, it is still impossible to ensure any clinical significance to the vast majority of all variants found through next-generation sequencing (NGS). There is a general concern that individuals and their clinical providers, when confronted with VUSs, will require additional unnecessary testing, with the potential for finding results with even more VUSs, thereby increasing patient's uncertainty and anxiety. Moreover, there is the additional concern that even when a variant is known to be pathogenic and highly penetrant in families with multiple affected individuals, the true penetrance of a variant when it is found in individuals with a negative family history may be much lower.

Therefore, risk assessment and genetic counseling in this context are challenging processes and depend on continually addressing recently available information and communicating it properly to healthcare providers and patients.

*Modern Medical Genetics and Genomics*

tion, and cardiomyopathy.

of genetic factors for most of common disorders or even for the susceptibility to infectious diseases. For complex chronic degenerative diseases of adult onset, their overall contribution of heritability has been identified, as life expectancy increases and high-throughput technologies improve. These provide the opportunity for understanding the interactions between the genetic and environmental factors of diseases such as cancer, Alzheimer's disease, diabetes mellitus, macular degenera-

In recent years, we have been facing the applications of modern genomics to the practice of medicine. With robust molecular biology technologies, one can identify the actionable mutations present in a tumor and establish the profile of its pattern of RNA expression, which are currently being used for determining prognosis and choosing appropriate targeted therapies for individual cancer patients. Another application is how modern genomic approaches are increasing our abilities in risk assessment and helping provide more accurate genetic counseling to patients and families affected with hereditary diseases as well as advances in prenatal diagnosis. There are further examples of applications of genomics to individualized health care: screening asymptomatic individuals for genetic predisposition to various diseases in order to improve health care, population-based newborn screening for preventable and treatable genetic diseases, identifying couples that are carriers for autosomal recessive or X-linked diseases that could affect their children before conception, prenatal screening of the fetus for aneuploidy by maternal cell-free DNA, and applications of pharmacogenomics on the detection of individual variation affecting drug therapy, which can be used to improve therapeutic efficacy and reduce adverse events.

At the beginning of the twenty-first century, the Human Genome Project (HGP) provided a virtually complete sequence of human genome from which now derives the efforts to catalog all human genes, understand their structure and regulation, determine the extent of their variation in different populations, and uncover how genetic variation contributes to susceptibility. The whole genome of any individual can now be sequenced rather than sequencing one gene at a time. These achievements are making possible the practice of genomic medicine, which aims at applying a wide analysis of the human genome and its products, including the epigenetic regulation of gene expression, gene variation, and their interactions with the environment, to medical care.

The HGP has now been succeeded by the Human Variome Project, which seeks to compile and share the huge variation in human DNA sequence worldwide. This is potentially possible since whole exome sequencing (WES) and whole genome sequencing (WGS) have been increasingly performed in several population studies. For example, the 100,000 Genomes Project in the United Kingdom have recently

The study of genetics and its role in causing human disease is now widely acknowledged as being among the most exciting and influential areas of medical research. Certainly, their valuable discoveries have benefited patients and families dramatically, but this achievement will be measured by translating them into both

Advances over the past few years in mutation identification have provided many improvements in risk assessment, carrier detection, and prenatal diagnosis, allowing the detection of particular mutations with almost 100% accuracy. Laboratory testing for pathogenic (disease-causing) mutations is available for more than 4,500 genes associated to over 11,000 genetic conditions [2]. The better knowledge of the genes involved in hereditary disease and the rapidly

achieved its goal of 100,000 genomes sequenced [1].

treatment and prevention of disease.

**3. Diagnostic advances**

**4**

## **4. Ethical dilemmas**

Each new advance in genetic technology has simultaneously brought new ethical concerns and raised new dilemmas about how science will be applied and utilized in medicine. At the center of this is the recognition that an individual's genetic background is fundamental to both their identity and possible disease susceptibility. The most controversial field is prenatal genetics and reproductive choice, though national legal frameworks and cultural practices vary widely worldwide. The debate surrounding the early ability to perform prenatal diagnosis for Down syndrome through invasive procedures in the mid-1960s is compared to the new technology that makes it possible to perform detailed genetic screening of the fetus on cell-free fetal DNA in the maternal blood or on embryos created through in vitro fertilization for preimplantation genetic diagnosis (PGD). Great controversy has taken place, and will go on, regarding the disclosure of unexpected but significant "incidental findings" from WES or WGS carried out for specific clinical purposes [4]. Furthermore today there is the technical feasibility of all newborns having their genome sequenced and screened for either childhood disorders or adult-onset conditions [5].

Advances in genetics attract great media attention, and this has brought the ethical debate to a wide public scenario. Issues about insurance, forensic science and DNA databases, patenting, gene therapy, population screening, cloning, stem cell research, and hybrids are considered to have major societal, commercial, and political importance and therefore impact clinical and laboratory practice in medical genetics. On a global scale, it is essential to safeguard fundamental principles such as privacy, confidentiality, and respect for human life at all stages and ages.

Many of the questions raised do not have easy or definitive answers, which means that there will be a great need for both public awareness and properly trained clinicians and counselors to balance the needs of their patients and families with these ethical challenges for the foreseeable future.

#### **5. Personalized and precision medicine**

The aim of personalized or individualized medicine is to use knowledge of an individual's genetic (or genomic) background relevant to the maintenance of health, prevention, and treatment of diseases as a routine part of medical care.

During the past 10 years, many examples of stratified medicine have blossomed, where the therapy of a particular disease is dependent on the germline or somatic variants patients may carry. These examples include monogenic rare diseases where a different treatment is recommended for patients with some types of germline mutations in a specific gene, such as *CFTR* gene mutations that cause cystic fibrosis, and the molecular therapy targeted on an actionable somatic mutation of a specific tumor, such as the *BRAF* V600E mutation in malignant melanoma. The genetic (or genomic) diagnosis is therefore a crucial step toward the most appropriate treatment and/or prevention, what is so-called clinical utility or actionability [6, 7]. Recent initiatives are focusing on improving health outcomes through precision medicine especially in Oncology [8] (**Table 1**). This is a multidisciplinary integrated approach that analyzes human samples and personal data to improve health care through increased precision in the knowledge of mechanisms of both disease and drug response.

Personalized genomic medicine (PGM) is only one component of precision medicine, which means, in a broadest sense, it requires clinical care providers to combine genomic information with other types of information, such as biochemical or physiological testing results, neurodevelopmental history, environmental exposures, and psychosocial experiences. The most important goal is provide more

**7**

**Author details**

Israel Gomy

provided the original work is properly cited.

Universidade Federal do Paraná, Curitiba, Brazil

\*Address all correspondence to<EMAIL_ADDRESS>
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

*Modern Medical Genetics and Genomics in the Era of Personalized/Precision Medicine*

Melanoma *BRAF, CDKN2A, KIT* Therapy; risk assessment; inherited

Breast and ovarian cancer *BRCA1, BRCA2* Therapy; inherited susceptibility

susceptibility

Therapy

Therapy; inherited susceptibility

Diagnosis; risk stratification

**Tumor(s) Genes Clinical application(s)**

*EPCAM, BRAF, KRAS, NRAS*

precise diagnosis, genetic counseling, management, prevention, and therapy. This effort has already got started, but plenty of work still needs to be done before PGM

*DOI: http://dx.doi.org/10.5772/intechopen.84578*

Colorectal cancer *MLH1, MSH2, MSH6, PMS2,*

Non-small-cell lung cancer *EGFR, BRAF, KRAS, ERBB2, RET,*

Myelodisplastic syndrome *TP53, GATA2, JAK2, ASXL1, ETV6,*

*Genetic/genomic profiling for selected malignancies (adapted from [8]).*

*MET, ALK, ROS1*

*RUNX1, SF3B1, EZH2*

Acute myeloid leukemia *KIT, CEBPA, FLT3, NPM1* Risk stratification

becomes integrated into medicine itself.

The author declares no conflict of interest.

**Conflict of interest**

**Table 1.**

*Modern Medical Genetics and Genomics in the Era of Personalized/Precision Medicine DOI: http://dx.doi.org/10.5772/intechopen.84578*

#### **Table 1.**

*Modern Medical Genetics and Genomics*

Each new advance in genetic technology has simultaneously brought new ethical concerns and raised new dilemmas about how science will be applied and utilized in medicine. At the center of this is the recognition that an individual's genetic background is fundamental to both their identity and possible disease susceptibility. The most controversial field is prenatal genetics and reproductive choice, though national legal frameworks and cultural practices vary widely worldwide. The debate surrounding the early ability to perform prenatal diagnosis for Down syndrome through invasive procedures in the mid-1960s is compared to the new technology that makes it possible to perform detailed genetic screening of the fetus on cell-free fetal DNA in the maternal blood or on embryos created through in vitro fertilization for preimplantation genetic diagnosis (PGD). Great controversy has taken place, and will go on, regarding the disclosure of unexpected but significant "incidental findings" from WES or WGS carried out for specific clinical purposes [4]. Furthermore today there is the technical feasibility of all newborns having their genome sequenced and screened

Advances in genetics attract great media attention, and this has brought the ethical debate to a wide public scenario. Issues about insurance, forensic science and DNA databases, patenting, gene therapy, population screening, cloning, stem cell research, and hybrids are considered to have major societal, commercial, and political importance and therefore impact clinical and laboratory practice in medical genetics. On a global scale, it is essential to safeguard fundamental principles such

as privacy, confidentiality, and respect for human life at all stages and ages. Many of the questions raised do not have easy or definitive answers, which means that there will be a great need for both public awareness and properly trained clinicians and counselors to balance the needs of their patients and families with

The aim of personalized or individualized medicine is to use knowledge of an individual's genetic (or genomic) background relevant to the maintenance of health, prevention, and treatment of diseases as a routine part of medical care.

in the knowledge of mechanisms of both disease and drug response.

Personalized genomic medicine (PGM) is only one component of precision medicine, which means, in a broadest sense, it requires clinical care providers to combine genomic information with other types of information, such as biochemical or physiological testing results, neurodevelopmental history, environmental exposures, and psychosocial experiences. The most important goal is provide more

During the past 10 years, many examples of stratified medicine have blossomed, where the therapy of a particular disease is dependent on the germline or somatic variants patients may carry. These examples include monogenic rare diseases where a different treatment is recommended for patients with some types of germline mutations in a specific gene, such as *CFTR* gene mutations that cause cystic fibrosis, and the molecular therapy targeted on an actionable somatic mutation of a specific tumor, such as the *BRAF* V600E mutation in malignant melanoma. The genetic (or genomic) diagnosis is therefore a crucial step toward the most appropriate treatment and/or prevention, what is so-called clinical utility or actionability [6, 7]. Recent initiatives are focusing on improving health outcomes through precision medicine especially in Oncology [8] (**Table 1**). This is a multidisciplinary integrated approach that analyzes human samples and personal data to improve health care through increased precision

for either childhood disorders or adult-onset conditions [5].

these ethical challenges for the foreseeable future.

**5. Personalized and precision medicine**

**4. Ethical dilemmas**

**6**

*Genetic/genomic profiling for selected malignancies (adapted from [8]).*

precise diagnosis, genetic counseling, management, prevention, and therapy. This effort has already got started, but plenty of work still needs to be done before PGM becomes integrated into medicine itself.

## **Conflict of interest**

The author declares no conflict of interest.

## **Author details**

Israel Gomy Universidade Federal do Paraná, Curitiba, Brazil

\*Address all correspondence to<EMAIL_ADDRESS>
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **References**

[1] Genomics England. Available from: https://www.genomicsengland.co.uk. [Accessed 01/31/19]

[2] Genetic testing registry. Available from: https://www.ncbi.nlm.nih.gov/gtr [Accessed: 01/31/19]

[3] Richards S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine. 2015;**17**:405-424. DOI: 10.1038/gim.2015.30

[4] Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 updated (ACMG SF v2.0): a A policy statement of the American College of Medical Genetics and Genomics. Genetics in Medicine. 2017;**19**:249-255. DOI: 10.1038/gim.2016.190

[5] Anderson, J. et al. Parents perspectives on whole genome sequencing for their children: qualified Qualified enthusiasm? Journal of Medical Ethics. 2017;**43**(8):535-539. DOI: 10.1136/medethics-2016-103564

[6] Chakravaty D et al. OncoKB: A precision oncology knowledge base JCO precision Oncology. 2017. Available from: https://oncokg.org. DOI: 10.1200/ PO.17.00011. [Accessed: 01/31/19]

[7] ClinGen. Actionability Working Group. Evidence-based Summaries. Available from: https://clinicalgenome. org/working-groups/actionability/ projects-initiatives/actionabilityevidence-based-summaries [Accessed: 01/31/19]

[8] National Comprehensive Cancer Network. Biomarker compendium. Available from: https://www.nccn. org/professionals/content/ [Accessed: 01/31/19]

**9**

Section 2

Reproductive and Prenatal

Genetics

## Section 2